Abstract
In 2000, Wyeth reported that the 3-quinolinecarbonitrile ring system was a template for EGFR inhibitors. It soon became apparent that the group at C-4 of this core was responsible for kinase selectivity. A 4-(2,4-dichloro-5- methoxyanilino) substituent provided potent inhibitors of Src, a non-receptor tyrosine kinase that plays a key role in cell signaling. One compound from this series, SKI-606, bosutinib, is currently in clinical trials for the treatment of cancer.
Keywords: 3-Quinolinecarbonitrile, kinase, Src, cancer, Abl, CML, SKI-606, bosutinib
Current Topics in Medicinal Chemistry
Title: Exploitation of the 3-Quinolinecarbonitrile Template for Src Tyrosine Kinase Inhibitors
Volume: 8 Issue: 10
Author(s): Diane H. Boschelli
Affiliation:
Keywords: 3-Quinolinecarbonitrile, kinase, Src, cancer, Abl, CML, SKI-606, bosutinib
Abstract: In 2000, Wyeth reported that the 3-quinolinecarbonitrile ring system was a template for EGFR inhibitors. It soon became apparent that the group at C-4 of this core was responsible for kinase selectivity. A 4-(2,4-dichloro-5- methoxyanilino) substituent provided potent inhibitors of Src, a non-receptor tyrosine kinase that plays a key role in cell signaling. One compound from this series, SKI-606, bosutinib, is currently in clinical trials for the treatment of cancer.
Export Options
About this article
Cite this article as:
Boschelli H. Diane, Exploitation of the 3-Quinolinecarbonitrile Template for Src Tyrosine Kinase Inhibitors, Current Topics in Medicinal Chemistry 2008; 8 (10) . https://dx.doi.org/10.2174/156802608784911653
DOI https://dx.doi.org/10.2174/156802608784911653 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antiangiogenic Therapy
Current Pharmaceutical Design Gestational Trophoblastic Neoplasia, an Ancient Disease: New Light and Potential Therapeutic Targets
Anti-Cancer Agents in Medicinal Chemistry Gene Therapy and Targeted Toxins for Glioma
Current Gene Therapy Carrier Deformability in Drug Delivery
Current Pharmaceutical Design Nutrition and NSCLC; Should We Administer Food Supplements?
Current Pharmaceutical Design Progress in Imaging Agents of Cell Apoptosis
Anti-Cancer Agents in Medicinal Chemistry Viral Based Gene Therapy for Prostate Cancer
Current Gene Therapy Heat Shock Protein 90 Inhibitors in Oncology
Current Proteomics Pharmacogenomics in Colorectal Cancer
Current Pharmacogenomics Clinical Evidence of Herb-Drug Interactions: A Systematic Review by the Natural Standard Research Collaboration
Current Drug Metabolism The Purinome, a Complex Mix of Drug and Toxicity Targets
Current Topics in Medicinal Chemistry CASC15: A Tumor-Associated Long Non-Coding RNA
Current Pharmaceutical Design Molecularly Targeted Therapy in Breast Cancer: The New Generation
Recent Patents on Anti-Cancer Drug Discovery Of Humans and Hamsters: The Hamster Buccal Pouch Carcinogenesis Model as a Paradigm for Oral Oncogenesis and Chemoprevention
Anti-Cancer Agents in Medicinal Chemistry Chemosensitization and Immunosensitization of Resistant Cancer Cells to Apoptosis and Inhibition of Metastasis by the Specific NF-κB Inhibitor DHMEQ
Current Pharmaceutical Design 10 Years of SELDI: What Have we Learnt?
Current Proteomics Microsatellite Instability as a Predictor of Outcomes in Colorectal Cancer in the Era of Immune-Checkpoint Inhibitors
Current Drug Targets Oncoproteomics of Neuroblastoma: A Blueprint for Future Progress
Current Proteomics Meet Our Editorial Board Member
Current Pharmaceutical Biotechnology Oncogenic LncRNA CASC9 in Cancer Progression
Current Pharmaceutical Design